Synektik (SNTP) Q3 2025 earnings summary

Executive summary

• Achieved consolidated revenue of PLN 154.2 million in Q3 FY2024, a 24% year-over-year increase, with strong growth in both equipment/IT and radiopharmaceuticals segments.

• Q1–Q3 FY2024 revenue stable at PLN 482.1 million, with recurring revenue up 66% to PLN 227.6 million.

• Net profit from continuing operations rose 36% year-over-year in Q3 FY2024 and 13% for Q1–Q3 FY2024.

• EBITDA from continuing operations rose 31% year-over-year in Q3, with margin improvement to 27%.

• Strategic focus on recurring revenue streams and expansion in medical therapy devices and radiopharmaceuticals.

Financial highlights

• Q3 FY2024 EBITDA from continuing operations reached PLN 41.6 million, up 31% year-over-year; net profit at PLN 30.5 million, up 36%.

• Q1–Q3 FY2024 EBITDA totaled PLN 122.5 million, up 12% year-over-year; net margin increased by 2.1 percentage points to 17.8%.

• Operating cash flow for 9M 2024: PLN 41.3 million; net cash decreased by PLN 38.9 million due to dividend and investment outflows.

• Dividend payout of PLN 70.4 million in the period.

• Cash surplus over financial liabilities of nearly PLN 16 million as of June 30, 2025.

Outlook and guidance

• Secured orders worth PLN 246 million in Q1–Q3 FY2024; active offers at PLN 137 million as of June 2025.

• Management expects continued growth in medical equipment, IT, and recurring service revenues, supported by new product launches and expansion in Central and Eastern Europe.

• Anticipates further growth in radiopharmaceuticals, driven by portfolio expansion and market development.

• Continued strong demand expected for medical equipment, driven by public healthcare investments and KPO funds.

• No formal financial guidance issued for FY2024.